Pfizer Inc. (PFE)
After hours:
| Previous close | 52.43 |
| Open | 52.04 |
| Bid | 52.28 x 1000 |
| Ask | 52.30 x 4000 |
| Day's range | 51.25 - 52.37 |
| 52-week range | 38.93 - 61.71 |
| Volume | |
| Avg. volume | 24,389,629 |
| Market cap | 293.506B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 11.78 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.60 (3.06%) |
| Ex-dividend date | 28 Jul 2022 |
| 1y target est | N/A |
- Business Wire
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
NEW YORK, June 30, 2022--Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are at high risk for progression to severe illness from COVID-19. PAXLOVID is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at lea
- Business Wire
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
NEW YORK & MAINZ, Germany, June 29, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration (FDA). The doses are planned to be delivered as soon as lat
- Business Wire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
NEW YORK, June 28, 2022--Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds
